- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04691011
New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis (IRM-SLA)
July 19, 2023 updated by: Assistance Publique Hopitaux De Marseille
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder.
There is no treatment that significantly slows progression.
Our project aims to find new biomarkers in MRI at three levels: cerebral, medullary and muscular.
These markers could allow an earlier diagnosis of the disease by showing more specific lesions of ALS and to quantify these lesions to measure the progression of the disease.
This study will use advanced Magnetic Resonance Imaging (MRI) techniques High field (3T) and very high field (7T) MRI.
Results from neurological and electrophysiological tests will be compared to the MRI.
Subjects will be recruited from ALS center of Marseille, France.
MRI will be done on ALS patients at baseline, at 3 month and at 6 month intervals.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
160
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jean Olivier Arnaud
Study Contact Backup
- Name: Shahram Attarian
- Phone Number: 33491386579
- Email: shahram.attarian@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13005
- Recruiting
- Shahram Attarian
-
Contact:
- Annie Verschueren
- Email: annie.verschueren@ap-hm.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Patients will be adults with a diagnosis of ALS.
- Healthy controls will also be recruited and will be age- and gender-matched to patients.
- Patients able to undergo a brain MRI for approximately an hour.
Exclusion Criteria:
- Subjects with other psychiatric or CNS or PNS diseases.
- Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign body, or significant claustrophobia that could affect the ability to have an MRI scan.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Muscle
|
MRI (1.5T)
MUNIX
|
Other: Spinal cord
|
MRI (1.5T)
MUNIX
7T and 3T MRI
|
Other: Brain
|
MRI (1.5T)
MUNIX
MRI (7T)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease progression using MRI
Time Frame: Change from Baseline and at Month 6
|
Muscular, brain and spinal cord MRI (brain sodium concentration, muscular volume of members, measure of transversal area for spinal cord)
|
Change from Baseline and at Month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Link between MRI and clinical scales
Time Frame: Baseline and Month 6
|
ALSFRS score, MRC score, ECAS score
|
Baseline and Month 6
|
Link between MRI and MUNIX
Time Frame: Baseline and Month 6
|
For muscle, brain and spinal cord group
|
Baseline and Month 6
|
Alterations of metabolic and funtional brain
Time Frame: Baseline and Month 6
|
Multiparametric MRI (diffusion parameters, myelin parameters, quantification of fat-infiltration and oedema)
|
Baseline and Month 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Emilie Garrido Pradalié, Direction Recherche Santé APHM
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 16, 2021
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
October 22, 2020
First Submitted That Met QC Criteria
December 30, 2020
First Posted (Actual)
December 31, 2020
Study Record Updates
Last Update Posted (Actual)
July 20, 2023
Last Update Submitted That Met QC Criteria
July 19, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-50
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on Muscular MRI
-
University Hospital, BordeauxTerminatedAmyotrophic Lateral Sclerosis | ALSFrance
-
Hospital Universitario La FeUnknown
-
Virginia Commonwealth UniversityRecruitingPeripheral Vascular DiseasesUnited States
-
Centre Hospitalier Régional d'OrléansRecruiting
-
Abbott Medical DevicesActive, not recruitingVentricular Septal DefectsUnited States, Canada
-
Universidade Norte do ParanáWithdrawn
-
University of HoustonAmerican Diabetes AssociationActive, not recruitingSedentary Lifestyle | Lipid Metabolism Disorders | Hyperinsulinemia | Aging Problems | Glucose Tolerance Impaired | Metabolic Disorder, Glucose | Low-density-lipoprotein-type | Inactivity, PhysicalUnited States
-
University of MilanCompleted
-
University Hospital, ToursCompletedNeuromuscular Diseases in Children | Neuromuscular Diseases in InfantsFrance
-
Seoul National University HospitalActive, not recruitingRespiratory InsufficiencyKorea, Republic of